Kallikrein-8 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Kallikrein-8 (UniProt O60259), expressed in HEK293 cells. Used for serine protease activity assays, substrate cleavage studies, inhibitor profiling, and antibody validation in neuroscience and skin biology research.
Expression system
HEK293
Cat. #
REC-Kallikrein8

In stock

SKU
REC-Kallikrein8
$498.00

Target Overview

Kallikrein-8 (KLK8; UniProt O60259) is a secreted serine protease of 260 amino acids belonging to the tissue kallikrein family (EC 3.4.21.118). This recombinant form is produced in HEK293 cells, an expression system well suited to human serine proteases that require mammalian glycosylation and disulfide bond formation for correct folding and activity. The protein encompasses the full-length mature sequence and retains the catalytic triad characteristic of kallikrein-family proteases. KLK8 cleaves a defined set of extracellular substrates — including casein, fibrinogen, kininogen, fibronectin, collagen type IV, and the neural cell adhesion molecule L1CAM — making it tractable for direct enzymatic activity assays using fluorogenic peptide substrates or native substrate cleavage followed by gel-based or mass spectrometry readouts. Its activity against L1CAM in hippocampal tissue has been characterised in the context of synaptic plasticity and memory formation, providing a biologically relevant substrate for in vitro cleavage studies. In the laboratory, this recombinant protein is used primarily for three purposes: (1) quantitative activity assays and kinetic parameter (Km, kcat) determination against synthetic and natural substrates; (2) inhibitor screening and IC50 determination for small molecules or endogenous protease inhibitors; and (3) antibody validation as a positive control antigen in Western blot, ELISA, and immunoassay development workflows. Researchers developing immunoassays for KLK8 in biofluids — such as plasma or cerebrospinal fluid — have relied on recombinant KLK8 as a reference standard and spike-in control. Researchers requiring a matched immunodetection reagent can pair this recombinant with Triple Point Biologics' Kallikrein-8 antibody (RP-Kallikrein8), validated for Western blot against human KLK8.

Background

Kallikrein-8 is a secreted serine endoprotease encoded by KLK8 and originally characterised in brain tissue under the name Neuropsin. It is expressed in the hippocampus, cerebral cortex, skin (keratinocytes), ovary, and other epithelial compartments, reflecting a functional range that spans neural plasticity, epidermal homeostasis, and extracellular matrix remodelling. In neural tissue, KLK8 has been characterised as a regulator of Schaffer-collateral long-term potentiation and synaptic bouton maturation, acting in part through extracellular cleavage of L1CAM following increases in neuronal activity. These properties have made KLK8 a subject of investigation in the context of memory acquisition and hippocampal circuit function. More recently, KLK8 has been studied in relation to Alzheimer's disease: Raza SA et al. (2026, Exp Neurol) reported that KLK8 contributes to kallikrein-kinin system dysregulation in Alzheimer's disease, situating it within a broader protease network relevant to neurodegeneration research. Separately, Gupta I et al. (2026, Brain Res) described the development of a fully automated immunoassay for plasma KLK8 evaluated in mild cognitive impairment — a study in which recombinant KLK8 served as a critical calibrant and spiking control, illustrating the direct utility of well-characterised recombinant material in biomarker assay development. Beyond the CNS, KLK8 participates in skin desquamation and keratinocyte proliferation, placing it within the cascade of epidermal kallikreins studied in psoriasis and related inflammatory dermatoses. In osteoarticular biology, Xu L et al. (2026, Tissue Cell) demonstrated that KLK8 promotes cartilage degradation and pyroptosis in osteoarthritis through activation of the NF-κB and NLRP3 inflammasome pathways — identifying it as a research target in joint disease models. Liu D et al. (2026, Aging Cell) further characterised age-dependent KLK8 upregulation and its contribution to susceptibility to ventilator-induced lung injury in aged mice, broadening the tissue contexts in which recombinant KLK8 is used as a tool for mechanistic in vitro studies. Across these research areas, recombinant KLK8 is used to establish enzymatic baselines, validate inhibitor candidates, and serve as antigen standard in immunodetection workflows. Its defined production in HEK293 cells ensures consistent glycosylation and activity profiles across experimental replicates — a practical consideration when comparing results across assay formats or between laboratories.

Applications

  • Fluorogenic peptide substrate cleavage activity assay (e.g., trypsin-like substrate profiling)
  • Kinetic parameter determination (Km, kcat) against casein, fibrinogen, or synthetic substrates
  • Small-molecule inhibitor IC50 screening in serine protease inhibitor panels
  • Positive control antigen for Western blot and ELISA using the matched RP-Kallikrein8 antibody
  • Calibration standard and spike-in control for plasma or CSF KLK8 immunoassay development
  • L1CAM extracellular domain cleavage assay for neural substrate specificity studies
  • Substrate identification by incubation with candidate extracellular matrix proteins followed by mass spectrometry
  • In vitro assessment of endogenous protease inhibitor (e.g., LEKTI, alpha-2-macroglobulin) interaction kinetics

References

  1. Raza SA et al. Kallikrein-8 contributes to kallikrein-kinin system dysregulation in Alzheimer's disease. Exp Neurol. 2026. doi:10.1016/j.expneurol.2026.115834 PMID: 42140379
  2. Gupta I et al. A fully automated immunoassay for plasma kallikrein-8: Development and evaluation in mild cognitive impairment. Brain Res. 2026. doi:10.1016/j.brainres.2026.150259 PMID: 41819517
  3. Xu L et al. KLK8 promotes cartilage degradation and pyroptosis in osteoarthritis by activating the NF-κB and NLRP3 inflammasome pathways. Tissue Cell. 2026. doi:10.1016/j.tice.2026.103427 PMID: 41793791
  4. Zhou X et al. Polyphyllin I mitigates psoriasiform inflammation and prevents relapse by modulating CLEC7A and inhibiting pyroptosis. Phytomedicine. 2026. doi:10.1016/j.phymed.2025.157658 PMID: 41435608
  5. Liu D et al. Age-Dependent KLK8 Upregulation Contributes to Elevated Susceptibility to Ventilator-Induced Lung Injury in the Elderly Mice. Aging Cell. 2026. doi:10.1111/acel.70304 PMID: 41310943

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; blood plasma; tissue

Frequently Asked Questions

What is the expected molecular weight of recombinant Kallikrein-8 on SDS-PAGE and Western blot?

Recombinant KLK8 (UniProt O60259) has a calculated MW of approximately 28.5 kDa for the mature secreted sequence, but HEK293-derived protein typically migrates at 30–35 kDa under denaturing conditions due to N-linked glycosylation. On reducing SDS-PAGE you should see a single predominant band in that range at >90% purity. Under non-reducing conditions, the band position may shift slightly if disulfide-linked forms are present. Run a fresh preparation alongside a molecular weight ladder calibrated in the 20–50 kDa range for the cleanest result.

Is this recombinant Kallikrein-8 the zymogen or the active mature form?

This product is the active mature form — the propeptide has been removed during processing in HEK293 cells, and the catalytic triad (His-Asp-Ser) is intact and competent. It is not the zymogen/inactive proform. If your experiment requires controlled activation from a precursor, this is not the right format. For studies of KLK8 enzymatic activity against casein, fibrinogen, fibronectin, L1CAM, or fluorogenic peptide substrates, the active enzyme is ready to use directly from the aliquot after equilibration to assay temperature.

What substrates and fluorogenic peptides work best for a Kallikrein-8 activity assay?

KLK8 is a trypsin-like serine protease with a preference for Arg/Lys at the P1 position. The fluorogenic peptide Boc-Val-Pro-Arg-AMC is commonly used for in vitro activity assays and provides a clean linear readout. Native macromolecular substrates including casein, fibrinogen, and L1CAM have been validated biochemically. For gel-based readout, incubate with casein at 37°C for 30–60 min and visualize cleavage by SDS-PAGE. Assay buffer of 50 mM Tris-HCl pH 7.5, 150 mM NaCl works well and is compatible with the supplied storage buffer — no desalting is typically required.

What assay buffer conditions and pH are optimal for recombinant Kallikrein-8 enzymatic activity?

KLK8 serine protease activity is optimal around pH 7.5–8.0. The supplied storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) is directly compatible with most activity assays at low enzyme dilutions, so glycerol carry-over is minimal. If you need to reduce glycerol below 0.1%, dialysis or gel filtration into assay buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl) is advisable. Including 0.01% BSA in the assay buffer helps prevent adsorptive losses at low protein concentrations (< 50 nM). Avoid reducing agents such as DTT above 1 mM, which can disrupt disulfide bonds essential for correct KLK8 folding.

What starting concentration of recombinant Kallikrein-8 should I use in an enzyme activity assay?

For fluorogenic peptide assays (e.g., Boc-Val-Pro-Arg-AMC at 100–200 µM substrate), a starting enzyme concentration of 1–10 nM is a reasonable range to establish linear kinetics. For native substrate cleavage (casein, fibrinogen), 50–200 nM KLK8 with a 30–60 minute incubation at 37°C typically yields visible cleavage bands. Titrate enzyme concentration in your first experiment to ensure you are in the linear portion of the velocity curve before running inhibitor IC50 measurements. All aliquots are supplied at a defined concentration stated on the CoA — use that as your stock reference.

Can I use recombinant Kallikrein-8 as a Western blot positive control for the RP-Kallikrein8 rabbit polyclonal antibody?

Yes — recombinant KLK8 (REC-Kallikrein8) is the recommended positive control for the matched RP-Kallikrein8 rabbit polyclonal antibody (see /anti-kallikrein-8-rabbit-polyclonal-antibody). Both are produced in-house and have been validated against the same antigen preparation. Load 20–50 ng of recombinant protein per lane on a 12% SDS-PAGE gel under reducing conditions. The antibody detects the recombinant and the endogenous protein at 30–35 kDa. This pairing is particularly useful for confirming antibody specificity alongside tissue lysates or conditioned medium samples where endogenous KLK8 expression may be low.

How much recombinant Kallikrein-8 should I load as a positive control to get a clean Western blot band?

20–50 ng per lane is the standard loading range when using the matched RP-Kallikrein8 antibody (SKU: RP-Kallikrein8) at a primary dilution of 1:1,000–1:2,000. At 20 ng you should see a clear band without significant background; at 50 ng the band is strong enough to serve as a reliable size marker reference at 30–35 kDa. If you are probing blots that also contain concentrated tissue lysate, load the recombinant in a flanking lane to avoid signal spillover. Running the positive control on every blot is especially valuable when working with low-expressing samples such as primary hippocampal neurons.

How should I store and handle recombinant Kallikrein-8 to preserve enzymatic activity over time?

Store at -20°C in single-use aliquots immediately upon receipt. Repeated freeze-thaw cycles progressively reduce enzymatic activity and should be avoided — aliquot to your typical experimental volume before the first use. Upon thawing, equilibrate on ice and use within the same working session where possible. The storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) stabilizes the protein at -20°C for at least 12 months from the manufacture date indicated on the CoA. Once thawed, keep on ice and complete assay setup within 2–4 hours. Do not dilute into water — use a compatible buffer to prevent denaturation at low ionic strength.

Validation imagery coming soon

Western blot validation figures for REC-Kallikrein8 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →